Please provide your email address to receive an email when new articles are posted on . An AI model accurately distinguished cardiac amyloidosis from other phenotypic mimics. The model also showed ...

Cardiac amyloidosis is an often-missed, life-threatening cause of heart failure. As new disease-modifying therapies emerge, timely and earlier diagnosis is critical. EchoGo® Amyloidosis is the first ...

ROCHESTER, Minn. — An artificial intelligence (AI) model developed by Mayo Clinic and Ultromics, Ltd., an AI echocardiography company based in Oxford, England, is highly accurate in screening for ...

"These forms of cardiac amyloidosis are rare but increasingly recognized. For the first time, patients with both forms of amyloidosis have undergone deep phenotyping using cardiac biomarkers, 12-lead ...

Researchers from Mayo Clinic and Ultromics, with investigators at the University of Chicago Medicine and global collaborators, validated and tested the model on a large and multiethnic patient ...

OXFORD, England, Jan. 10, 2024 /PRNewswire/ -- Ultromics, a patient outcomes-focused AI-driven health technology company with roots at the University of Oxford, UK, has entered into an agreement with ...

England-based Ultromics’ AI technology could improve detection of cardiac amyloidosis on routine echocardiograms, according to a new study from the company. The results were presented at the American ...

Cardiac amyloidosis, or "stiff heart syndrome," is a rare manifestation of amyloidosis, which carries the worst prognosis of any involved organ. Researchers have developed a new technique that they ...

BALTIMORE — Myocardial scintigraphy, which is molecular imaging of the heart, can be used to predict major adverse cardiac events (MACE) in patients with transthyretin-type amyloidosis, according to ...

Amyloid cardiomyopathy (cardiac amyloidosis) is a form of restrictive cardiomyopathy that can result in significant progressive diastolic congestive heart failure. As the name suggests, amyloid ...

NEW YORK, June 18, 2018 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. (NASDAQ:FBIO) Company developing treatments for rare and life-threatening diseases, today ...

(MENAFN- PR Newswire) Researchers from Ultromics and Mayo Clinic, with investigators at The University of Chicago Medicine and collaborators around the world, validated and tested the model in a large ...